AKT3 has been found to be significantly associated with the EMT process of the thyroid (You et al., 2020), bladder (McNiel and Tsichlis, 2017), colorectal (Buikhuisen et al., 2021), and prostate cancer (Galbraith et al., 2021). Here, AKT3 is linked to prostate cancer.